Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes

Headache

Volumn 52, Issue 7, 2012, Pages 1085-1093

  Bérard, Anick ^a,b   Kori, Shashidhar ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MAP Pharmaceuticals Inc   (United States)

Author keywords

DHE; low birth weight; major congenital malformations; prematurity; Quebec Pregnancy Registry; spontaneous abortion

Indexed keywords

DIHYDROERGOTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; TRIPTAN DERIVATIVE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CANADA; CASE CONTROL STUDY; CONGENITAL MALFORMATION; CONTROLLED STUDY; FEMALE; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COHORT STUDIES; CONGENITAL ABNORMALITIES; DIHYDROERGOTAMINE; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; INFANT, PREMATURE; MIGRAINE DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; QUEBEC; REGISTRIES; RISK FACTORS; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 84863727869     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02172.x     Document Type: Article

References (33)

1. Airola G, Allais G, Castagnoli GI, Rolando S, Mana O, Benedetto C,. Non-pharmacological management of migraine during pregnancy. Neurol Sci. 2010; 31 (Suppl. 1): S63-S65.
2. Pfaffenrath V, Rehm M,. Migraine in pregnancy: What are the safest treatment options? Drug Saf. 1998; 19: 383-388.
3. Alcantara J, Cossette M,. Intractable migraine headaches during pregnancy under chiropractic care. Complement Ther Clin Pract. 2009; 15: 192-197.
4. Duong S, Bozzo P, Nordeng H, Einarson A,. Safety of triptans for migraine headaches during pregnancy and breastfeeding. Can Fam Physician. 2010; 56: 537-539.
5. Nezvalova-Henriksen K, Spigset O, Nordeng H,. Maternal characteristics and migraine pharmacotherapy during pregnancy: Cross-sectional analysis of data from a large cohort study. Cephalalgia. 2009; 29: 1267-1276.
6. Lucas S,. Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep. 2009; 13: 392-398.
7. Contag SA, Mertz HL, Bushnell CD,. Migraine during pregnancy: Is it more than a headache? Nat Rev Neurol. 2009; 5: 449-456.
8. Silberstein SD,. Headaches in pregnancy. J Headache Pain. 2005; 6: 172-174.
9. Banhidy F, Acs N, Puho E, Czeizel AE,. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br J Clin Pharmacol. 2007; 64: 510-516.
10. Acs N, Banhidy F, Puho E, Czeizel AE,. A possible dose-dependent teratogenic effect of ergotamine. Reprod Toxicol. 2006; 22: 551-552.
11. Mellander S, Nordenfelt I,. Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation. Clin Sci. 1970; 39: 183-201.
12. Aellig WH,. Direct effects of vasoactive substances on superficial human veins in vivo. Int Angiol. 1985; 4: 235-242.
13. Aellig WH, Rosenthaler J,. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol. 1986; 30: 581-584.
14. Torres A, Ena Regidor P,. Pharmacological response of the association of chlorpromazine and dihydroergotamine on the guinea pig uterus and the pregnant uterus in women. Clin Lab (Zaragoza). 1955; 60: 1-5.
15. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-9). 9th revision. Geneva: World Health Organization; 1978.
16. Bérard A, Lacasse A,. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Can J Clin Pharmacol. 2009; 16: 360-369.
17. Essebag V, Genest J Jr, Suissa S, Pilote L,. The nested case-control study in cardiology. Am Heart J. 2003; 146: 581-590.
18. Vilain A, Otis S, Forget A, Blais L,. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Saf. 2008; 17: 345-353.
19. Nakhai-Pour HR, Broy P, Bérard A,. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ. 2010; 182: 1031-1037.
20. Heinonen O, Slone D, Shapiro S,. Birth Defects and Drugs in Pregnancy. Littleton, CO: Publishing Sciences Group; 1977.
21. Kulaga S, Zargarzadeh AH, Bérard A,. Prescriptions filled during pregnancy for drugs with the potential of fetal harm. BJOG. 2009; 116: 1788-1795.
22. Facchinetti F, Allais G, Nappi RE, et al,. Migraine is a risk factor for hypertensive disorders in pregnancy: A prospective cohort study. Cephalalgia. 2009; 29: 286-292.
23. Nakhai-Pour HR, Rey E, Bérard A,. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol. 2010; 89: 147-154.
24. Bradley PB, Humphrey PP, Williams RH,. Evidence for the existence of 5-hydroxytryptamine receptors, which are not of the 5-HT2 type, mediating contraction of rabbit isolated basilar artery. Br J Pharmacol. 1986; 87: 3-4.
25. Hool-Zulauf B, Stürmer E,. Oxytocic activity of two dihydrogenated ergot peptide alkaloids on the rabbit uterus in situ. Arzneimittelforschung. 1977; 27: 2323-2325.
26. Aellig WH,. Venoconstrictor effect of dihydroergotamine in superficial hand veins. Eur J Clin Pharmacol. 1974; 7: 137-139.
27. Nezvalová-Henriksen K, Spigset O, Nordeng H,. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: Results from the Norwegian Mother and Child Cohort Study. Headache. 2010; 50: 563-575.
28. Bánhidy F, Acs N, Horváth-Puhõ E, Czeizel AE,. Pregnancy complications and delivery outcomes in pregnant women with severe migraine. Eur J Obstet Gynecol Reprod Biol. 2007; 134: 157-163.
29. Nakhai-Pour HR, Broy P, Sheehy O, Bérard A,. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011; 183: 1713-1720.
30. Ofori B, Oraichi D, Blais L, Rey E, Bérard A,. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006; 77: 268-279.
31. Källén B, Nilsson E, Otterblad Olausson P,. Delivery outcome after maternal use of drugs for migraine: A register study in Sweden. Drug Saf. 2011; 34: 691-703.
32. Bérard A, Kulaga S, Nakhai-Pour HR,. Magnitude of confounding caused by missing information in the studies on adverse pregnancy outcomes. Pharmacoepidemiol Drug Saf. 2009; 18 (Suppl.): 156.
33. Einarson A, Choi J, Einarson TR, Koren G,. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: Results from a large prospective database. J Obstet Gynaecol Can. 2009; 31: 452-456.